DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Daptomycin in Treating Neutropenia and Fever in Patients With Cancer

Information source: OHSU Knight Cancer Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Fever; Sweating; Hot Flashes; Infection; Neutropenia; Unspecified Adult Solid Tumor, Protocol Specific

Intervention: Daptomycin (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: OHSU Knight Cancer Institute

Official(s) and/or principal investigator(s):
Joseph Bubalo, PharmD, Principal Investigator, Affiliation: OHSU Knight Cancer Institute

Summary

RATIONALE: Antibiotics, such as daptomycin, may control neutropenia, fever, and infection in patients with cancer. PURPOSE: This phase II trial is studying how well daptomycin works in treating neutropenia and fever in patients with cancer.

Clinical Details

Official title: Phase II Open Label Pilot Trial of Empiric Daptomycin Treatment for Oncology Patients With Neutropenic Fever

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Primary outcome: Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin.

Detailed description: OBJECTIVES: Primary

- Assess the response rate to therapy within 72 hours of starting daptomycin in cancer

patients with neutropenic fever. Secondary

- Assess the percentage of bacterial cures in patients with documented gram-positive

bacterial infections.

- Assess time to afebrile state.

- Assess the pharmacokinetic data of daptomycin in neutropenic patients.

- Document the incidence of breakthrough infections that require a change of therapy or

additional agents to clear.

- Assess the tolerability of daptomycin in neutropenic patients.

- Assess and document adverse events and toxicity due to daptomycin.

OUTLINE: This is an open-label, pilot study. Patients first receive standard treatment for gram-negative bacteria for 72 hours. If the patient is still febrile at 72 hours, daptomycin is administered. Patients receive daptomycin IV over 30 minutes once daily. Patients who are afebrile, not neutropenic (absolute neutrophil count [ANC] > 500/mm³), and have no signs of infection after 72 hours of therapy may discontinue daptomycin. Patients who are afebrile and neutropenic (ANC < 500/mm³) after 72 hours of therapy continue to receive daptomycin until absolute neutrophil count (ANC) > 500/mm³ for 2 consecutive days. Patients who are febrile with or without continued neutropenia (ANC < 500/mm³) after 72 hours of therapy continue to receive daptomycin for up to 10-14 days in the absence of unacceptable toxicity. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

DISEASE CHARACTERISTICS:

- Diagnosis of cancer

- Diagnosis of neutropenic fever

- Temperature > 38. 3°C once OR ≥ 38°C twice within 12 hours

- Absolute neutrophil count < 500/mm^³ and ≥ 1 of the following:

- Mucositis

- Concurrent skin or soft tissue infection

- Indwelling catheter and/or suspected catheter infection

- Recent quinolone prophylaxis

- Positive blood cultures for gram-positive cocci before final identification

or other documented gram-positive pathogen

- Colonization with β-lactam resistant gram-positive organisms (commonly the

nares or the skin)

- Hypotension, tachycardia, narrowed pulse pressures, tachypnea, or other

signs of cardiovascular compromise

- Expected duration of neutropenia ≥ 3 days

- No known infection with daptomycin-resistant organism or gram-negative organism and

not yet meeting criteria for the addition of gram-positive antimicrobial therapy

- No suspected meningitis or osteomyelitis

- No documented or suspected gram-positive pneumonia

- No suspected or proven endocarditis

PATIENT CHARACTERISTICS:

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Life expectancy ≥ 2 weeks

- Creatinine clearance ≥ 50 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective double-method contraception

- No known sensitivity to daptomycin or product excipients

- No history of or concurrent rhabdomyolysis

- No HIV positivity

- No psychiatric disorders that would preclude study compliance

- No signs or symptoms of myopathy with creatine phosphokinase (CPK) elevation > 1,000

U/L (5 times upper limit of normal [ULN])

- No CPK elevations > 10 times ULN in patients with no signs or symptoms of

myopathy PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- At least 7 days since prior daptomycin or other antibiotic agents covering

gram-positive organisms

- No concurrent hemodialysis or continuous ambulatory peritoneal dialysis

- No concurrent succinylcholine, ethanol, fludrocortisone, olanzapine, or pioglitazone

- No concurrent hydroxymethyl glutaryl (HMG) coenzyme A (HMG CoA) reductase inhibitors

(e. g., lovastatin, simvastatin, atorvastatin)

- Concurrent therapy for gram-negative bacterial infection allowed

Locations and Contacts

OHSU Knight Cancer Institute, Portland, Oregon 97239, United States
Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: December 2006
Last updated: May 24, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017